FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024401484> ?p ?o ?g. }

• W2024401484 endingPage "811" @default.
• W2024401484 startingPage "805" @default.
• W2024401484 abstract "To understand the threat posed by localized prostate cancer and the potential impact of surgery or radiation, patients and healthcare providers require information on long-term outcomes following conservative management. To describe 15-yr survival outcomes and cancer therapy utilization among men 65 years and older managed conservatively for newly diagnosed localized prostate cancer. This is a population-based cohort study with participants living in predefined geographic areas covered by the Surveillance, Epidemiology, and End Results program. The study includes 31 137 Medicare patients aged ≥65 yr diagnosed with localized prostate cancer in 1992–2009 who initially received conservative management (no surgery, radiotherapy, cryotherapy, or androgen deprivation therapy [ADT]). All patients were followed until death or December 31, 2009 (for prostate cancer–specific mortality [PCSM]) and December 31, 2011 (for overall mortality). Competing-risk analyses were used to examine PCSM, overall mortality, and utilization of cancer therapies. The 15-yr risk of PCSM for men aged 65–74 yr diagnosed with screening-detected prostate cancer was 5.7% (95% confidence interval [CI] 3.7–8.0%) for T1c Gleason 5–7 and 22% (95% CI 16–35%) for Gleason 8–10 disease. After 15 yr of follow-up, 24% (95% CI 21–27%) of men aged 65–74 yr with screening-detected Gleason 5–7 cancer received ADT. The corresponding result for men with Gleason 8–10 cancer was 38% (95% CI 32–44%). The major study limitations are the lack of data for men aged <65 yr and detailed clinical information associated with secondary cancer therapy. The 15-yr outcomes following conservative management of newly diagnosed Gleason 5–7 prostate cancer among men aged ≥65 yr are excellent. Men with Gleason 8–10 disease managed conservatively face a significant risk of PCSM. We examined the long-term survival outcomes for a large group of patients diagnosed with localized prostate cancer who did not have surgery, radiotherapy, cryotherapy, or androgen deprivation therapy in the first 6 mo after cancer diagnosis. We found that the 15-yr disease-specific survival is excellent for men diagnosed with Gleason 5–7 disease. The data support conservative management as a reasonable choice for elderly patients with low-grade localized prostate cancer." @default.
• W2024401484 created "2016-06-24" @default.
• W2024401484 creator A5005424988 @default.
• W2024401484 creator A5009692912 @default.
• W2024401484 creator A5013633423 @default.
• W2024401484 creator A5026667667 @default.
• W2024401484 creator A5057266942 @default.
• W2024401484 creator A5090879940 @default.
• W2024401484 date "2015-11-01" @default.
• W2024401484 modified "2023-10-13" @default.
• W2024401484 title "Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer" @default.
• W2024401484 cites W1969314733 @default.
• W2024401484 cites W1983414502 @default.
• W2024401484 cites W1999781922 @default.
• W2024401484 cites W2014516834 @default.
• W2024401484 cites W2032194590 @default.
• W2024401484 cites W2033791152 @default.
• W2024401484 cites W2057847137 @default.
• W2024401484 cites W2110569728 @default.
• W2024401484 cites W2121103668 @default.
• W2024401484 cites W2125837480 @default.
• W2024401484 cites W2127031670 @default.
• W2024401484 cites W2127088268 @default.
• W2024401484 cites W2137704198 @default.
• W2024401484 cites W2143802196 @default.
• W2024401484 cites W2144286150 @default.
• W2024401484 cites W2145221548 @default.
• W2024401484 cites W2146822966 @default.
• W2024401484 cites W2156549595 @default.
• W2024401484 cites W2156776019 @default.
• W2024401484 cites W2157358083 @default.
• W2024401484 cites W2161817637 @default.
• W2024401484 cites W2337728056 @default.
• W2024401484 cites W2905153461 @default.
• W2024401484 cites W4232514081 @default.
• W2024401484 cites W4233182856 @default.
• W2024401484 doi "https://doi.org/10.1016/j.eururo.2015.03.021" @default.
• W2024401484 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4575827" @default.
• W2024401484 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25800944" @default.
• W2024401484 hasPublicationYear "2015" @default.
• W2024401484 type Work @default.
• W2024401484 sameAs 2024401484 @default.
• W2024401484 citedByCount "58" @default.
• W2024401484 countsByYear W20244014842015 @default.
• W2024401484 countsByYear W20244014842016 @default.
• W2024401484 countsByYear W20244014842017 @default.
• W2024401484 countsByYear W20244014842018 @default.
• W2024401484 countsByYear W20244014842019 @default.
• W2024401484 countsByYear W20244014842020 @default.
• W2024401484 countsByYear W20244014842021 @default.
• W2024401484 countsByYear W20244014842022 @default.
• W2024401484 countsByYear W20244014842023 @default.
• W2024401484 crossrefType "journal-article" @default.
• W2024401484 hasAuthorship W2024401484A5005424988 @default.
• W2024401484 hasAuthorship W2024401484A5009692912 @default.
• W2024401484 hasAuthorship W2024401484A5013633423 @default.
• W2024401484 hasAuthorship W2024401484A5026667667 @default.
• W2024401484 hasAuthorship W2024401484A5057266942 @default.
• W2024401484 hasAuthorship W2024401484A5090879940 @default.
• W2024401484 hasBestOaLocation W20244014842 @default.
• W2024401484 hasConcept C107130276 @default.
• W2024401484 hasConcept C121608353 @default.
• W2024401484 hasConcept C126322002 @default.
• W2024401484 hasConcept C2777899217 @default.
• W2024401484 hasConcept C2778162587 @default.
• W2024401484 hasConcept C2778527826 @default.
• W2024401484 hasConcept C2780192828 @default.
• W2024401484 hasConcept C2908647359 @default.
• W2024401484 hasConcept C29456083 @default.
• W2024401484 hasConcept C509974204 @default.
• W2024401484 hasConcept C71924100 @default.
• W2024401484 hasConcept C72563966 @default.
• W2024401484 hasConcept C99454951 @default.
• W2024401484 hasConceptScore W2024401484C107130276 @default.
• W2024401484 hasConceptScore W2024401484C121608353 @default.
• W2024401484 hasConceptScore W2024401484C126322002 @default.
• W2024401484 hasConceptScore W2024401484C2777899217 @default.
• W2024401484 hasConceptScore W2024401484C2778162587 @default.
• W2024401484 hasConceptScore W2024401484C2778527826 @default.
• W2024401484 hasConceptScore W2024401484C2780192828 @default.
• W2024401484 hasConceptScore W2024401484C2908647359 @default.
• W2024401484 hasConceptScore W2024401484C29456083 @default.
• W2024401484 hasConceptScore W2024401484C509974204 @default.
• W2024401484 hasConceptScore W2024401484C71924100 @default.
• W2024401484 hasConceptScore W2024401484C72563966 @default.
• W2024401484 hasConceptScore W2024401484C99454951 @default.
• W2024401484 hasIssue "5" @default.
• W2024401484 hasLocation W20244014841 @default.
• W2024401484 hasLocation W20244014842 @default.
• W2024401484 hasLocation W20244014843 @default.
• W2024401484 hasLocation W20244014844 @default.
• W2024401484 hasOpenAccess W2024401484 @default.
• W2024401484 hasPrimaryLocation W20244014841 @default.
• W2024401484 hasRelatedWork W1963763301 @default.
• W2024401484 hasRelatedWork W2035098213 @default.
• W2024401484 hasRelatedWork W2522846761 @default.
• W2024401484 hasRelatedWork W2728894889 @default.
• W2024401484 hasRelatedWork W2753537866 @default.

• next